Trial Profile
An Exploratory First Time in Human (FTIH) Study Investigating the Pharmacokinetics (PK), Immunogenicity, Safety and Tolerability of GSK2434735 Administered as a Single Low Dose in Healthy Male Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 2434735 (Primary) ; GSK 2434735 (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors GSK
- 01 Jun 2012 Actual patient number (5) added as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.